当前位置: 首页 > 详情页

Systemic inflammation and insulin resistance-related indicator predicts poor outcome in patients with cancer cachexia

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Beijing Shijitan Hosp, Dept Gastrointestinal Surg, Dept Clin Nutr, 10 Tie Yi Rd, Beijing 100038, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Dept Nephrol, 10 Tie Yi Rd, Beijing 100053, Peoples R China [3]Key Lab Canc FSMP State Market Regulat, 10 Tie Yi Rd, Beijing 100038, Peoples R China [4]Capital Med Univ, Lab Clin Med, Clin Lab Med, 10 Tie Yi Rd, Beijing 100038, Peoples R China [5]Sichuan Univ, West China Hosp, Clin Nutr Dept, Chengdu 610041, Sichuan, Peoples R China [6]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Pathol, Natl Canc Ctr, Beijing 100038, Peoples R China [7]Guangxi Med Univ, Sch Preclin Med, Dept Parasitol, Nanning 530021, Peoples R China [8]Yunnan Univ, Kunming 650091, Yunnan, Peoples R China [9]Gen Surg Clin Med Ctr Yunnan Prov, Kunming 650032, Yunnan, Peoples R China
出处:
ISSN:

关键词: Systemic inflammation Insulin resistance CTI Overall survival

摘要:
BackgroundThe C-reactive protein (CRP)-triglyceride-glucose (TyG) index (CTI), which is a measure representing the level of inflammation and insulin resistance (IR), is related to poor cancer prognosis; however, the CTI has not been validated in patients with cancer cachexia. Thus, this study aimed to explore the potential clinical value of the CTI in patients with cancer cachexia.MethodsIn this study, our prospective multicenter cohort included 1411 patients with cancer cachexia (mean age 59.45 +/- 11.38, 63.3% male), which was a combined analysis of multiple cancer types. We randomly selected 30% of the patients for the internal test cohort (mean age 58.90 +/- 11.22% 61.4% male). Additionally, we included 307 patients with cancer cachexia in the external validation cohort (mean age 61.16 +/- 11, 58.5% male). Receiver operating characteristic (ROC) and calibration curves were performed to investigate the prognostic value of CTI. The prognostic value of the CTI was also investigated performing univariate and multivariate survival analyses.ResultsThe survival curve indicated that the CTI showed a significant prognostic value in the total, internal, and external validation cohorts. Prognostic ROC curves and calibration curves revealed that the CTI showed good consistency in predicting the survival of patients with cancer cachexia. Multivariate survival analysis showed that an elevated CTI increased the risk of death by 22% (total cohort, 95% confidence interval [CI] = 1.13-1.33), 34% (internal test cohort, 95%CI = 1.11-1.62), and 35% (external validation cohort, 95%CI = 1.14-1.59) for each increase in the standard deviation of CTI. High CTI reliably predicted shorter survival (total cohort, hazard ratio [HR] = 1.45, 95%CI = 1.22-1.71; internal test cohort, HR = 1.62, 95%CI = 1.12-2.36; external validation cohort, HR = 1.61, 95%CI = 1.15-2.26). High CTI significantly predicted shorter survival in different tumor subgroups, such as esophageal [HR = 2.11, 95%CI = 1.05-4.21] and colorectal cancer [HR = 2.29, 95%CI = 1.42-3.71]. The mediating effects analysis found that the mediating proportions of PGSGA, ECOG PS, and EORTC QLQ-C30 on the direct effects of CTI were 21.72%, 19.63%, and 11.61%, respectively We found that there was a significant positive correlation between the CTI and 90-day [HR = 2.48, 95%CI = 1.52-4.14] and 180-day mortality [HR = 1.77,95%CI = 1.24-2.55] in patients with cancer cachexia.ConclusionThe CTI can predict the short- and long-term survival of patients with cancer cachexia and provide a useful prognostic tool for clinical practice.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 3 区 医学
小类 | 3 区 细胞生物学 3 区 肿瘤学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 细胞生物学 3 区 肿瘤学
JCR分区:
出版当年[2022]版:
Q1 ONCOLOGY Q2 CELL BIOLOGY
最新[2023]版:
Q1 CELL BIOLOGY Q1 ONCOLOGY Q2 CELL BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing Shijitan Hosp, Dept Gastrointestinal Surg, Dept Clin Nutr, 10 Tie Yi Rd, Beijing 100038, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Dept Nephrol, 10 Tie Yi Rd, Beijing 100053, Peoples R China [3]Key Lab Canc FSMP State Market Regulat, 10 Tie Yi Rd, Beijing 100038, Peoples R China [4]Capital Med Univ, Lab Clin Med, Clin Lab Med, 10 Tie Yi Rd, Beijing 100038, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Capital Med Univ, Beijing Shijitan Hosp, Dept Gastrointestinal Surg, Dept Clin Nutr, 10 Tie Yi Rd, Beijing 100038, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Dept Nephrol, 10 Tie Yi Rd, Beijing 100053, Peoples R China [3]Key Lab Canc FSMP State Market Regulat, 10 Tie Yi Rd, Beijing 100038, Peoples R China [4]Capital Med Univ, Lab Clin Med, Clin Lab Med, 10 Tie Yi Rd, Beijing 100038, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院